Canandaigua National Corp Has $2.37 Million Stake in Eli Lilly and Company (NYSE:LLY)

Canandaigua National Corp trimmed its position in Eli Lilly and Company (NYSE:LLYGet Rating) by 4.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,311 shares of the company’s stock after selling 329 shares during the period. Canandaigua National Corp’s holdings in Eli Lilly and were worth $2,370,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of LLY. CFM Wealth Partners LLC boosted its position in Eli Lilly and by 13.5% during the 2nd quarter. CFM Wealth Partners LLC now owns 3,147 shares of the company’s stock worth $1,020,000 after acquiring an additional 375 shares during the last quarter. Cooper Financial Group bought a new stake in Eli Lilly and during the 2nd quarter worth about $235,000. Wedmont Private Capital boosted its stake in shares of Eli Lilly and by 83.3% during the 2nd quarter. Wedmont Private Capital now owns 7,535 shares of the company’s stock worth $2,443,000 after buying an additional 3,425 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of Eli Lilly and by 14.1% in the 2nd quarter. Revolve Wealth Partners LLC now owns 810 shares of the company’s stock valued at $263,000 after acquiring an additional 100 shares in the last quarter. Finally, Brookstone Capital Management boosted its position in Eli Lilly and by 22.6% during the second quarter. Brookstone Capital Management now owns 35,534 shares of the company’s stock valued at $11,743,000 after purchasing an additional 6,541 shares during the last quarter. 82.45% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

LLY has been the topic of several analyst reports. StockNews.com raised shares of Eli Lilly and from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 14th. JPMorgan Chase & Co. raised their price objective on Eli Lilly and from $340.00 to $355.00 in a research report on Wednesday, June 1st. Morgan Stanley boosted their target price on Eli Lilly and from $395.00 to $412.00 and gave the stock an “overweight” rating in a report on Wednesday, September 7th. BMO Capital Markets raised their price target on Eli Lilly and from $369.00 to $396.00 and gave the company an “outperform” rating in a report on Tuesday, September 6th. Finally, Citigroup upped their price objective on shares of Eli Lilly and from $285.00 to $370.00 in a report on Thursday, August 25th. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Eli Lilly and has an average rating of “Moderate Buy” and an average price target of $330.44.

Eli Lilly and Price Performance

Shares of NYSE:LLY opened at $308.89 on Monday. The company has a current ratio of 1.10, a quick ratio of 0.85 and a debt-to-equity ratio of 1.70. The stock has a market capitalization of $293.50 billion, a PE ratio of 49.26, a PEG ratio of 2.00 and a beta of 0.38. The firm has a 50 day moving average of $316.13 and a 200-day moving average of $303.88. Eli Lilly and Company has a 12 month low of $220.20 and a 12 month high of $335.33.

Eli Lilly and (NYSE:LLYGet Rating) last released its earnings results on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.86 by ($0.61). Eli Lilly and had a return on equity of 85.58% and a net margin of 19.58%. The business had revenue of $6.49 billion for the quarter, compared to the consensus estimate of $6.85 billion. During the same quarter in the previous year, the company earned $1.87 earnings per share. The firm’s revenue for the quarter was down 3.7% on a year-over-year basis. On average, equities research analysts predict that Eli Lilly and Company will post 7.97 EPS for the current fiscal year.

Eli Lilly and Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 9th. Shareholders of record on Monday, August 15th were paid a dividend of $0.98 per share. This represents a $3.92 annualized dividend and a yield of 1.27%. The ex-dividend date was Friday, August 12th. Eli Lilly and’s payout ratio is 62.52%.

Insider Transactions at Eli Lilly and

In related news, major shareholder Lilly Endowment Inc sold 89,458 shares of the stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $332.85, for a total value of $29,776,095.30. Following the completion of the transaction, the insider now owns 103,875,441 shares of the company’s stock, valued at approximately $34,574,940,536.85. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, major shareholder Lilly Endowment Inc sold 89,458 shares of the stock in a transaction on Thursday, July 28th. The stock was sold at an average price of $332.85, for a total value of $29,776,095.30. Following the completion of the transaction, the insider now directly owns 103,875,441 shares in the company, valued at approximately $34,574,940,536.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jackson P. Tai purchased 656 shares of Eli Lilly and stock in a transaction dated Friday, August 12th. The shares were purchased at an average price of $304.19 per share, for a total transaction of $199,548.64. Following the completion of the acquisition, the director now owns 62,857 shares of the company’s stock, valued at approximately $19,120,470.83. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 753,125 shares of company stock valued at $242,744,201. 0.12% of the stock is currently owned by insiders.

Eli Lilly and Company Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Articles

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.